H.R. 7953In committeeHealth care
FDA could fast-track drugs already approved abroad under new bill
Data as of July 11, 2026
The FAIR Act would let the FDA approve life-threatening disease drugs within 30 days if already approved in the EU, UK, or Canada.45-second read · 4 questions answered below
Decoded
What does this do?
The bill creates a fast-track FDA approval process for drugs treating life-threatening diseases that are already legally sold in the European Union, United Kingdom, or Canada. The FDA would have 30 days to decide, but could later withdraw approval if new safety evidence emerges or the foreign regulator withdraws its own approval. It also speeds up permission to start U.S. clinical trials using foreign authorization, with the same 30-day window.
Who does it affect?
This mainly affects patients with rare or life-threatening diseases seeking new treatments, and pharmaceutical and biotech companies developing those drugs. The FDA would also be affected, needing new review processes and a report to Congress after five years.
Why does it matter?
Relying on foreign regulatory decisions to speed up U.S. approvals raises questions about whether this affects the FDA's usual safety review standards.
Where does it stand?
- Introduced
- House committee — You are here
- House vote
- Senate
- President's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
AI-drafted summary. Verify it against the official text before you act on it.
Three steps: where you stand, your script, the call.
Make the callSee how a call works
Official title
FAIR ACT
- Introduced:
- March 17, 2026
- Latest action:
- March 17, 2026
Referred to the House Committee on Energy and Commerce.
Read the official bill on Congress.govMake the call
Three steps: where you stand, your script, the call.